Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:34:23 EST Tue 14 Jan 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - http://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  282.00.03·0.0440.00.035460.715250.035  0.035  0.0350.06  0.025Jan 13Dec 1215 min RT 2¢
TSX - T282.00.03·0.0440.00.035205.27110.035  0.035  0.0350.06  0.025Jan 1315 min
NEO ATS - U 0.03572.0320.035  0.035  0.035Jan 1315 min
Alpha - A 0.03530.0110.035  0.035  0.035Jan 1315 min
Omega - O 0.03515.0110.035  0.035  0.035Jan 1315 min
CX2 - H 0.03595.0340.035  0.035  0.035Jan 1315 min
CXD - D 0.0350.31    Nov 1315 min
TriAct - M 0.0351.23    Sep 11/2015 min
CS2 - S 0.03542.0120.035  0.035  0.035Jan 1315 min

Recent Trades - Last 10 of 25
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-12-12 08:15C:APLI0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLI0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLI0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLI0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLI0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLI0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
2024-11-06 18:20C:APLI0.035News ReleaseAppili shareholders approve Aditxt deal
2024-11-06 08:30C:APLI0.04News ReleaseAditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
2024-10-31 14:51C:APLI0.035News ReleaseAppili receives feedback from FDA for ATI-1801 plan
2024-10-31 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
2024-10-30 17:35C:APLI0.035News ReleaseAppili Therapeutics to host conference call Nov. 1
2024-10-29 08:15C:APLI0.035News ReleaseSylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives
2024-10-28 08:15C:APLI0.035News ReleaseAditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
2024-10-17 07:15C:APLI0.035News ReleaseAppili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek(TM) 2024
2024-10-10 16:07C:APLI0.025News ReleaseAppili acquiror Aditxt comments on acquisition
2024-10-10 16:02C:APLI0.025News ReleaseAppili corrects share acquisition price
2024-10-10 14:58C:APLI0.025News ReleaseAppili to hold special meeting Nov. 6 over Aditxt deal
2024-10-03 17:03C:APLI0.025News ReleaseAppili acquiror Aditxt needs $17M for acquisition
2024-09-17 17:36C:APLI0.03News ReleaseAppili shareholders approve AGM resolutions